SLS 21RS-408 **ENGROSSED**

2021 Regular Session

1

SENATE BILL NO. 168

BY SENATOR FRED MILLS

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

CONTROL DANGER SUBSTANCE. Provides relative to controlled dangerous substances. (8/1/21)

AN ACT

2	To enact R.S. 40:964(Schedule I)(A)(72) through (79), (Schedule II)(B)(30), and (Schedule
3	IV)(B)(57) and to repeal R.S. 40:964(Schedule V)(F), relative to the Uniform
4	Controlled Dangerous Substances Law; to add certain substances to Schedules I, II,
5	and IV; to repeal certain substances in Schedule V; to provide for technical changes
6	by the Louisiana Law Institute; and to provide for related matters.
7	Be it enacted by the Legislature of Louisiana:
8	Section 1. R.S. 40:964(Schedule I)(A)(72) through (79),(Schedule II)(B)(30), and
9	(Schedule IV)(B)(57) are hereby enacted to read as follows:
10	§964. Composition of schedules
11	Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.
12	40:962, consist of the following drugs or other substances, by whatever official
13	name, common or usual name, chemical name, or brand name designated:
14	SCHEDULE I
15	A. Opiates. Unless specifically excepted or unless listed in another schedule,
16	any of the following opiates, including their isomers, esters, ethers, salts, or salts of
17	isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers,

SLS 21RS-408

ENGROSSED
SB NO. 168

1 or salts is possible within the specific chemical designation: 2 3 (72) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-4 piperidinyl|-N-phenylpropanamide) (73) Brorphine (1-(1-(4-bromophenyl) ethyl) piperidin-4-yl)-1,3-5 dihydro-2H-benzimidazol-2-one) 6 (74) Crotonyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-7 8 enamide) 9 Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-(75) 10 phenylcyclopentanecarboxamide) 11 (76) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-12 phenylisobutyramide) (77) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-13 14 phenethylpiperidin-4-yl)isobutyramide) 15 (78) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1phenethylpiperidin-4-yl)butyramide) 16 17 (79) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-18 phenylpentanamide) 19 20 **SCHEDULE II** 21 B. Opiates. Unless specifically excepted or unless listed in another schedule, 22 any of the following opiates, including its isomers, esters, ethers, salts, and salts of 23 24 isomers, esters, ethers, and salts is possible within the specific chemical designation, 25 dextrorphan and levopropoxyphene excepted: 26 27 (30) Oliceridine 28 SCHEDULE IV 29

SB NO. 168 1 2 B. Depressants. 3 Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following 4

substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

8

(57) Remimazolam

10

Section 2. R.S. 40:964(Schedule V)(F) is hereby repealed.

Section 3. The Louisiana State Law Institute is hereby authorized and directed to renumber the substances in R.S. 40:964(Schedule I)(A), (Schedule II)(B), and (Schedule IV)(B) to ensure that the substances are in alphabetical order.

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Brandi Cannon.

DIGEST

SB 168 Engrossed

5

6

7

9

11

12

13

14

2021 Regular Session

Fred Mills

<u>Present law</u> provides for the designation of controlled dangerous substances into Schedules I, II, III, IV, and V based upon the substances' potential for addiction and abuse.

Proposed law adds Beta-hydroxythiofentanyl, Brorphine, Crotonyl fentanyl, Cyclopentyl fentanyl, Isobutyryl fentanyl, Para-chloroisobutyryl fentanyl, Para-methoxybutyryl fentanyl, and Valeryl fentanyl to Schedule I.

Proposed law adds Oliceridine to Schedule II.

Proposed law adds Remimazolam to Schedule IV.

Proposed law removes cannabidiol when contained in a drug product approved by the U.S. Food and Drug Administration from Schedule V.

Effective August 1, 2021.

(Adds R.S. 40:964(Schedule I)(A)(72)-(79), (Schedule II)(B)(30), and (Schedule IV)(B)(57); repeals R.S. 40:964(Schedule V)(F))